Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
5-Amino-1MQ
Category 1Metabolic · Research compound (multiple suppliers)
Small molecule NNMT inhibitor (not a peptide). Promotes fat oxidation, NAD+ synthesis, and mitochondrial biogenesis by selectively blocking nicotinamide N-methyltransferase.
About
Clinical Dosing
Not FDA-approved. Small molecule NNMT inhibitor, not classified as a peptide. Not subject to FDA Cat 1/Cat 2 peptide restrictions.
Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials. Oral route (50-150 mg daily) is primary in community/clinic use; SC route shown here for calculator purposes.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
SC Research Protocol
Source: Community protocol based on Neelakantan et al., Biochemical Pharmacology, 2018
| Dose | Duration | Draw (10 mg vial in 2mL) | Notes |
|---|---|---|---|
| 150 mcg | 2 weeks | 0.03 mL (3 units) | Starting SC dose |
| 250 mcg | Maintenance | 0.05 mL (5 units) | Standard SC dose. Typical cycles: 8-12 weeks on, 4 weeks off |
Available Vial Sizes
10 mg
10 mg vial
50 mg
50 mg vial
Citations
- [1]Selective and Membrane-Permeable Small Molecule Inhibitors of NNMT Reverse High-Fat-Diet-Induced Obesity in Mice. Biochemical Pharmacology, 147, 141-152. Link(Reviewed: 2026-04-12)
- [2]Nicotinamide N-methyltransferase Knockdown Protects Against Diet-Induced Obesity. Nature Medicine, 20(6), 608-614. Link(Reviewed: 2026-04-12)